Drug Profile
ZD 0892
Latest Information Update: 15 Sep 2000
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Peripheral vascular disorders
Most Recent Events
- 15 Sep 2000 Discontinued-I for Chronic obstructive pulmonary disease in United Kingdom (Unknown route)
- 15 Sep 2000 Discontinued-I for Peripheral vascular disorders in United Kingdom (Unknown route)
- 19 May 1999 Phase-I clinical trials for Chronic obstructive pulmonary disease in United Kingdom (Unknown route)